5 Protect IP to Keep American Tech at the Top - Politics Information

Protect IP to Keep American Tech at the Top


By Paul R. Michel


America can't outcompete low-wage countries when it comes to manufacturing cheap, mass-produced widgets.

But we can -- and historically have -- outcompeted every other nation when it comes to creating superior technology, from semiconductors and smartphone operating systems to advanced medicines.

Unfortunately, this advantage is disappearing. Competitor nations have greatly improved their policies which enable technological breakthroughs.

America is heading in the opposite direction. Our leaders are actively weakening the patents, trademarks, copyrights, and other intellectual property protections that incentivize companies to make investments in new technologies.

Until recently, the U.S. patent system was the global "gold standard." It was imitated by other nations, particularly archrival China. Over the past few years, China has upgraded its system to the point that, in many respects, it now surpasses our own. Patents are more rapidly granted, remedies to prevent IP theft are more common, and the laws are modernized almost annually. The list goes on.

Meanwhile, the United States has been weakening its patent system. In 2011, Congress over-reacted to exaggerated complaints by Big Tech companies about "patent trolls," -- firms that buy up patents and sue reputable companies for infringement -- and instituted a powerful tribunal inside the U.S. Patent and Trademark Office that usually invalidates patents challenged there.

The Supreme Court has also made challenging patents easier, made injunctions to stop infringement generally unavailable, and shrank the scope of inventions eligible for patenting. Today, many important inventions held ineligible for patenting here are eligible throughout Europe and in China.

This represents a huge failure of U.S. leadership.

Fortunately, leaders are emerging in the U.S. Senate who are focused on reviving patents to invigorate economic growth and job creation: Senators Coons, Tillis, Hirono, and Cotton. They are leading efforts to make more inventions eligible for patenting.

Separately, Senators Schumer and Young are proposing to increase federal funding for technology by sponsoring the American Innovation and Competition Act.

This effort is vital to U.S. recovery in economy and technology because public funding, which helps spur private sector innovation, has been shrinking for decades -- as has private investment. Venture capital firms insist on their clients obtaining ownership rights before committing the needed funds. So, prospects for our future prosperity rise or fall in line with the strength of IP protections.

However, Big Tech has convinced many of their colleagues to leave matters alone. Their legions of lobbyists swarm Capitol Hill, suggesting that patent revival is not necessary. Only a few members, such as those named above, understand the link between robust patents and economic revival.

Economic progress requires fixing our ailing patent system. And we must do so soon -- before China replaces us as the world's leader in the advanced technologies that will dominate the 21st Century.

Paul R. Michel served on the United States Court of Appeals for the Federal Circuit for 22 years, and as its chief judge from 2004 until his retirement in 2010. This piece originally ran in VentureBeat.

More Resources


04/22/2024
University Safe Spaces Only for Terrorist Supporters


more info


04/22/2024
Why Anti-Israel Protesters Won't Stop Harassing Jews


more info


04/22/2024
Who's Behind the Anti-Israel Protests


more info


04/22/2024
What Donald Trump Fears Most


more info


04/22/2024
Biden and the Blame America First Democrats


more info


04/22/2024
Earth Day: It Doesn't Have To Be 'Mother Nature Versus Man'


more info


04/22/2024
Obamas, Media Feed Children's Climate Anxiety
This type of children's content on climate change may seem ridiculous, but it's widespread.

more info


04/22/2024
Why Are Voters Worried About Biden's Age?
It's all about appearances.

more info


04/22/2024
Opposition to Trump Rooted in Contempt for Regular Voters
In Trump, his supporters hear a spirited defense of the hard-working despised and a fearless denouncing of the fashionable despisers.

more info


04/22/2024
Pennsylvania Will Be Rubber Match of 2024 Election
RCP Washington bureau chief Carl Cannon and senior elections analyst Sean Trende discuss President Biden's effort to win Pennsylvania for a second time with Andrew Walworth on Friday's edition of the RealClearPolitics radio show (SiriusXM's POTUS Channel 124, M-F at 6:00 pm):

more info


04/22/2024
Inside Todd Blanche's Plan To Keep Trump Out of Jail
Twelve jurors seated. He just needs one.

more info


04/22/2024
Why Is Trump Barred From Discussing Cohen & Daniels?
Breaking news, live coverage of US politics, foreign affairs, economics, and more from the Washington Examiner. Objective news, conservative opinion.

more info


04/22/2024
Trump's Trial Challenge: Being Stripped of Control
NEW YORK - Sir, can you please have a seat. Donald Trump had stood up to leave the Manhattan criminal courtroom as Justice Juan M. Merchan was wrapping up a scheduling discussion Tuesday. But the judge had not yet adjourned the court or left the bench. Trump, the 45th president of the United States and the owner of his own company, is used to setting his own pace. Still, when Merchan admonished him to sit back down, the former president did so without saying a word. Sign up for The Morning new

more info


04/22/2024
Five Ways Dems Are Trying To Turn America Into Venezuela
Here are five ways the American left's current rhetoric & policies are eerily reminiscent of Venezuela's collapse into communist oppression.

more info


04/22/2024
Speaker Johnson Establishes Himself as a Titan of Congress
A miracle just happened in Washington, D.C.

more info



Custom Search

More Politics Articles:

Related Articles

5 Financial Pressure Points To Evaluate During COVID Times


Financial pressure is a part of life for most people, and now the COVID-19 pandemic has brought new financial pressure points or exacerbated existing ones for many individuals and families.

Why Are People Complaining About Innovative COVID Treatments?


Gilead Sciences just announced it will charge $3,120 for a full course of Remdesivir, the first new FDA-approved treatment for COVID-19. Some knee-jerk members of Congress like Lloyd Doggett (D-Tex.) immediately condemned that price tag as "outrageous." The Institute for Clinical and Economic Review, a left-leaning nonprofit that releases its own recommendations of "fair" drug prices, claimed that Gilead could afford to price Remdesivir as low as $10 per course of treatment -- the cost of the raw ingredients used to make the drug.

Proposed Healthcare Reforms Will Not Help the Latinx Community


Joe Biden is officially the Democratic presidential nominee, all thanks to his moderate reputation.

Trade Enforcement Can Accelerate America's Economic Recovery


The stock market has largely rebounded from COVID-19 and American retail sales are improving steadily. Even more encouraging is that the U.S. unemployment rate fell for the fifth consecutive month in September. Each of these gains are sure signs that the Trump administration's economic response to the coronavirus crisis is working.

Drug Price Controls: Right Objective, Wrong Solution


This month, President Trump signed an executive order to reduce Medicare spending on prescription drugs. For each medication, Medicare will pay no more than the lowest price available in other developed countries.

Keep Thanksgiving, Family and Friends Alive


Joe Biden or Donald Trump will never visit me in my home, stand beside me at the funeral home or dance at my wedding. I will not be receiving any calls from either of them to pray for me during sickness or to check on how my children are doing. I probably will never sit in a room with them to visit, laugh and tell funny stories or just to hang out over a cup of coffee. I do not personally know either one. I welcome the opportunity to visit with either of them, but doubt it will happen.

The "E" Stands for “Excellence:” Remembering Walter E. Williams


Walter E. Williams, prolific author, piercing cultural commentator, old school economist (that’s a good thing), devoted husband, loving father, and long-time friend of Grove City College has passed from this world.

How Congress Can Really Fix Surprise Billing


House and Senate leaders recently agreed on legislation to end surprise medical bills as part of a big coronavirus relief package. President Trump signed it into law at the end of December.

A Federal Rule Will Reverse Strides in Cancer Treatment


"You've got cancer." That's one of the scariest sentences in the English language.

Biden Must Restore Seniors' Access to Essential Medicines


On January 19, Medicare officials announced a new payment model that could wreak havoc on the chronically ill.

Violence In America, Don't Be Surprised


The most recent attack at the United States Capitol will most likely insure a permanent fence and additional security. The attack which resulted in the loss of life for a long serving Capitol police officer and the attacker is another senseless violent act.

Protecting the Innovation that Protects Global Health


The most far-reaching healthcare policy decision of 2021 won't be made in Congress or the White House. It will be made at the World Trade Organization, which is considering a petition to waive all patent rights on Covid-19 vaccines.

Don't Repeat Europe's Vaccine Catastrophe


For many Americans, the calamitously slow vaccine roll-out in countries like Germany, France, and Italy comes as a surprise. After all, in the early days of the pandemic, Europe's response to the crisis seemed highly competent, especially compared to the United States.

A Full Plate for the New U.S. Trade Czar


The newly confirmed U.S. trade representative, Katherine Tai, is about as qualified as a person can be for the job. Which is a good thing, because she already faces a series of challenges.

Don't Let the US Import Europe's Failed Cancer Policies


With a majority in both the House and Senate and control of the Oval Office, Democratic leaders are excited about the prospect of making significant changes. One good example of this is the House Democrats' "Lower Drug Costs Now Act."